Semaglutide for weight loss in advanced interstitial lung disease: A Pilot Study

Recruiting
18 years - 99 years
All
Phase N/A
10 participants needed
1 Location

Brief description of study

The aim of the pilot study is to demonstrate feasibility and tolerability of semaglutide in patients with obesity and advanced ILD. 

Detailed description of study

Semaglutide is a antidiabetic medication that has been known to help with long-term weight-loss management. The aim is to see the tolerability of the medication in patients with ILDs to promote weight-loss for feasibility of further pulmonary treatment. This is a 22-week study, during which you will be asked to work with the research study team and meet with them to complete research procedures. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research,Interstitial Lung Disease,Obesity
  • Age: 18 years - 99 years
  • Gender: All

- Diagnosis of an Interstitial Lung Disease
- BMI > 35 kg/m2
- Requires supplemental oxygen on exertion
- Semaglutide prescribed by primary pulmonologist
- Insurance approval

Updated on 04 Aug 2024. Study ID: 851742

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center